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1. Introduction 
Lung cancer is the number one cause of cancer-related deaths worldwide. It claims 1.3 
million lives every year (www.who.int/mediacentre) (1). To understand the mechanism of 
lung carcinogenesis is one of the essential tasks for effective control of lung cancer. Lung 
cancer and other cancers have long been viewed as “genetic diseases” (2, 3). Particularly, 
tumor suppressor gene (TSG) deactivation plays a critical role in carcinogenesis. 
Historically, majority of the scientific evidence on tumor suppressor gene-related 
carcinogenesis describes the genetic defects occurring either in the TSGs themselves, such as 
mutations, or in their environment, such as activation of their inhibitors. Therapeutic 
applications of such knowledge against cancers have been attempted through reconstituting 
wild-type TSG products in target cells/tissues by genetic manipulation or biological or 
chemical molecules, thereby restoring the functions of TSGs and possibly slowing cancer 
progression. 
Ever since the 'two-hit' hypothesis (4) and the first proposal of a potential tumor suppressor 
gene being involved in the retinoblastomas formation (5), especially after the function of 
wild-type p53 gene was clearly described (6, 7), the therapeutic research effort has been 
shifted from optimizing the non-specific radiation and chemotherapy that mainly kill fast-
dividing cells to targeting the specific genetic changes. Restoring the function of TSGs has 
been considered as one of the most promising directions for cancer therapy.  
Directly transfecting TSGs into the cancer cells to restore the function of the TSGs and 
inhibit the tumor growth has become a promising direction to develop novel cancer therapy 
for the past two decades. Adenoviral and retroviral vectors have been used to deliver TSGs 
into human tumors by intratumoral or regional administration. The best example is the 
adenoviral carried wild-type p53 gene used to treat patients with non-small cell lung cancer 
(NSCLC) by direct intratumoral injection (8). Nonviral gene delivery methods such as 
cationic liposomes and cationic polymers were also developed for delivering TSGs because 
of their distinct advantage of lack of immunogenicity (9-11). Our lab has developed a unique 
cationic liposomal p53 and cationic polymers p53 to treat orthotopic human NSCLC model 
in mice with intratracheal or aerosol administration, which significantly enhanced the gene 
delivery efficiency to the airway epithelium and markedly reduced the systemic toxicity, the 
results showed a great therapeutic potential in the preclinical orthotopic human NSCLC 
xenografts in mice (12, 13). 
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However, the overall efficacy of these TSG therapies by direct gene transfection or delivery 
was limited. One of the important reasons is that most cases of “loss of function” found in 
tumor tissues are at the mature stage of the carcinogenesis process, at which moment the 
multiple irreversible genetic defects are established already, therefore, it is very difficult to 
reverse the carcinogenesis process by restoring or correcting the functions of one or a few 
TSGs. 
More recently, increasing evidence, particularly the “cancer stem cell” model suggests that 
epigenetic changes, which occur in normal stem or progenitor cells, are the earliest events in 
cancer initiation (14). Therefore, to catch the early cancer-specific epigenetic changes and 
reverse them logically becomes a better strategy than those focusing on the irreversible 
genetic defects.  
Multiple research groups have demonstrated that correcting the aberrant methylation in the 
promoter region of TSGs could inhibit cancer development. Among these studies, we have 
directly proved the concept in the orthotopic lung cancer models in mice. Briefly, we first 
proved that azacytidine (Aza), a demethylation agent, could effectively demethylate the 
hypermethylated promoter of RASSF1a gene (a TSG), at non-cytotoxic concentration range 
which was a thousand fold lower than its cytotoxic concentration. Then we used 
intratracheal injection of Aza at a non-cytotoxic dose to treat the airway inoculated NSCLC 
xenografts in mice, and we found that the demethylation treatment significantly prolonged 
the life of the tumor-bearing mice, and the locoregional therapy for localized lung cancer in 
the airway epithelium was significantly superior than the systemic (IV) treatment. Our 
results demonstrated that the model NSCLC could be inhibited if the TSGs were reactivated 
by the reversal of the hypermethylation in the promoter regions. In this chapter, we will also 
discuss the possible application, the advantages and limitation of the current epigenetic 
methods aimed to enhance cancer therapeutic efficacy by promoting TSGs. 
Restoring TSG functions through epigenetic manipulations will be a promising strategy for 
cancer therapy and prevention, which shifts the focus from treating cells with irreversible 
genetic lesions to targeting the reversible epigenetic changes. Further work in this field will 
complement our knowledge of TSG-expression control and enhance our understanding of 
the carcinogenesis process. This exciting new therapeutic strategy could potentially reduce 
cancer mortality when applied to populations of individuals at risk. 
In this chapter we will briefly summarize the studies describing the aberrant epigenetic 
alterations in lung cancer and the methods to control carcinogenesis with epigenetic 
manipulations, particularly, through controlling TSGs. We will also outline advances in the 
potential use of these epigenetic events for cancer diagnosis, prognosis and targeted 
epigenetic therapy, and present an experimental study of demethylation therapy at the 
preclinical level.  
2. Epigenetic changes and lung cancer 
Epigenetic changes usually are heritable changes in gene expression level without alteration 
of DNA sequence. Unlike genetic changes, epigenetic changes are reversible. The normal 
epigenetic process is important for gene expression and genome stability. When this normal 
process is disrupted, carcinogenesis may start. Therefore, epigenetic changes are considered 
a key player in the onset and progression of different type of cancers including lung cancer. 
The most frequently reported epigenetic phenomena are chromatin modifications including 
post-translational modifications of histones and chromatin modifying complexes, non-
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coding RNAs mediated regulations, and particularly DNA methylation. Epigenetic 
processes are finely tuned, undergo many regulations in response to the environment, and 
involve almost all the signaling pathways described in the literature. Epigenetics plays a 
crucial role in the control of nuclear architecture and gene activity and constitutes one of the 
bases of the biological diversity. In the first part of this chapter, we mainly focus on DNA 
methylation and its links to TSGs and lung cancer.  
2.1 DNA methylation and lung cancer 
DNA methylation is the most widely studied epigenetic modification restricted to the DNA 
motif called CpG dinucleotides, i.e. cytosine followed by guanine residues (15). Enriched in 
genomic regions known as “CpG islands,” these CpG dinucleotides are typically at least 200 
bp and up to several Kb in length with a high GC percentage, and are mainly found near or 
at the transcription start site within the promoter of about 40% of mammalian genes. CpG 
islands play a major role in the process of transcriptional regulation, and the ability of a 
gene to be or not to be transcribed is correlated with the unmethylated and methylated 
status of a CpG island, respectively, in the presence of the required co-regulators. 
Methylation is the only covalent modification of the DNA in mammalian cells and carries 
out normal physiological functions during embryonic development (16), genomic 
imprinting (17), and chromosome-X inactivation (18). However, frequent alterations in DNA 
methylation are observed in cancers such as hypermethylation of CpG islands at tumor 
suppressor gene (TSG) loci leading to the loss of their expression, genome-wide 
hypomethylation in the body of genes and in DNA repetitive sequences leading to genomic 
instability (16), and altered DNA methyltransferases (DNMTs) expression (17). 
DNA hypermethylation in the promoter region of TSGs is frequently found in human lung 
cancer tissues and cell lines. It was proved to be responsible for silencing the TSG and 
therefore promoting the initiation and development of the lung carcinogenesis. The best-
studied example is the case of p16INK4a (CDKN2A); its promoter hypermethylation 
prevents the negative control exerted by p16INK4a on RB phosphorylation, thereby 
promoting cell cycle progression. p16INK4a hypermethylation is considered as one of the 
earliest event in lung tumorigenesis and increases constantly with disease progression (19, 
20). An increasing number of other genes have been investigated for their methlyation status 
in lung cancer, including h-cadherin (CDH13) (21), 14-3-3σ (22), death associated protein 
kinase 1 (DAPK1) (23), ras association domain family 1 gene (RASSF1a) (24), caspase-8 (25), 
retinoic acid receptor β-2 (RAR-β), tissue inhibitor of metalloproteinase 3 (TIMP3), o6-
methylguanine DNA methyltransferase (MGMT), E-cadherin (ECAD), gluthatione s-
transferase p1 (GSTP1) (26), FHIT (27, 28), ASC/TMS1, HSRBC, TSLC1, DAL-1, and PTEN 
(29). Since these genes are involved in a broad range of biological processes, such as cancer 
cell cycle regulation, proliferation, apoptosis, cell adhesion, mobility, and DNA repair, 
promoter DNA hypermethylation may be a key event in lung carcinogenesis. Furthermore, 
genome-wide analyses have suggested that the presence of promoter DNA 
hypermethylation is probably more extensive than previously thought (30-33). For instance, 
Shames et al. recently identified 132 genes that are methylated with high penetrance in lung 
cancer cells (32). More strikingly, Brena et al. reported that 4.8% of all CpG island promoters 
might be aberrantly methylated, suggesting that the expression of about 1,400 genes might 
be disturbed in lung cancer (30).  
Due to the spontaneous hydrolytic deamination under physiological conditions, methylated 
cytosine can be considered as a potent endogenous mutagen for C to T mutations, therefore 
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DNA hypermethylation can actually predispose to mutational events (14). Although 
representing only 1% of the bases in the mammalian genome, methylated cytosine might be 
responsible for as much as 30% of all transition mutations found in human disease such as 
cancers (34, 35). 
The mechanism of the aberrant hypermethylation in the promoter region of TSGs in human 
non-small-cell lung cancer especially among smoker patients was described as the 
overexpression of DNA methyltranferases including DNMT1, DNMT3A and DNMT3B. 
Interestingly, polymorphisms that influence expression of the DNMT3B gene have been 
connected with increasing risk of lung cancer (36, 37). An adverse consequence of methylation 
of CpG sites appears to facilitate the binding for benzo[a]pyrene, a carcinogen, found in 
cigarette smoke, leading to the formation of major DNA damage hotspots in human lung 
cancer (38, 39). A well-illustrated example of this phenomenon is the occurrence of some 
hotspot mutations of the p53 tumor suppressor gene in lung tumors (40, 41).  
Clinical evidence also showed that TSG promoter methylation is associated with the 
smoking history of patients with lung cancer. In lung adenocarcinomas and squamous cell 
carcinomas, the frequency of p16, MGMT, RASSF1, MTHFR, and FHIT promoter 
methylation was significantly higher among smokers than never-smokers (42-45); but the 
promoter methylation of other genes such as RASSF2, TNFRSF10C, BHLHB5, and BOLL 
was higher in never-smoker lung cancer patients than those of smokers (46, 47), suggesting 
smoking may target specific genes for methylation. 
The roles of methylation in lung cancers for early detection, risk assessment, disease 
progression, and prognosis have also been studied. DNA methylation may serve as a 
marker for the early detection of lung cancer when found in the sputum of the patient (19, 
48). For example, p16INK4a and MGMT promoter methylation could predict the 
development of squamous cell carcinoma up to three years before clinical diagnosis (49, 50), 
and RASSF1A, APC, ESR1, ABCB1, MT1G, and HOXC9 genes were found more frequently 
methylated in stage I lung adenocarcinomas/squamous cell carcinomas than the non-
cancerous lesions (51), whereas the prevalence of hDAB2IP, H-cadherin, DAL-1, and FBN2 
methylation was associated significantly with advanced stage of lung cancer (52-54). 
Altogether, theses studies highlight promoter methylation as a promising epigenetic 
approach for early detection and prognosis of NSCLC.  
Demethylating drugs have great and promising clinical potential based on their ability to 
restore the expression of epigenetic silenced TSGs and inhibit tumor cell growth, while 
inducing manageable short-term side effects at the effective doses (55). The 5-aza-2′-
deoxycytidine demethylating agent has been reported to increase the survival of 
chemotherapy-naive NSCLC patients, up to 6 years in some cases (56), although the 
relatively high dose in the treatment could be suspected to contribute partially cytotoxic 
effect to the final therapeutic outcome. More therapeutic investigations are underway, 
aiming at combining the demethylating agents with histone deacetylase inhibitors and 
attempting to integrate epigenetic therapy with more standard therapy. 
2.2 Chromatin modifications and lung cancer 
Chromatin is formed by basic units called the nucleosome, which is assembled by wrapping 
approximately 147 bp of genomic DNA around a histone octamere containing two copies of 
each of the core histones H2A, H2B, H3 and H4. The core histones possess an amino-
terminal tail that protrudes outside of the nucleosome, which are subjected to a wide  
variety of post-translational covalent modifications such as acetylation, methylation, 
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phosphorylation and ubiquitinylation. Access to the chromatin is thus affected by these 
modifications and therefore influences almost all DNA-based processes. Consequently, the 
structure and integrity of the genome and normal patterns of gene expression are potentially 
affected by the global alterations of histone modification patterns. 
The protein complexes that regulate transcription by modifying histones or altering 
chromatin structure are mainly represented by Histones AcetylTransferases 
(HATs)/Histones Deacetylases (HDACs) and Histones methyltransferases 
(HMTs)/Histones Demethylases (DHMTs) complexes that determine the level of acetylation 
and methylation, respectively, of the amino-terminal domains of nucleosomal histones 
associated with them, and by ATP-dependent complexes such as SWI/SNF which use the 
energy of ATP hydrolysis to locally disrupt or alter the association of histones with DNA. 
Histone deacetylation mediated by HDACs works synergistically to alter the chromatin 
condensation status and represses transcription with DNMTs and a group of methylated 
DNA-binding proteins (57). In general, high HDAC activity is associated with condensed, 
transcriptionally inactive chromatin. 
Altered expression pattern of histone and chromatin modifying enzymes have been found 
in human tumors, and histone modifications may contribute to tumorigenesis (58, 59). A 
clinical study including 138 lung cancer patients demonstrated that changes in global levels 
of histone 3 lysine 4 dimethylation (H3K4diMe), histone 3 lysine 9 acetylation (H3K9Ac), 
and histone 2A lysine 5 acetylation (H2AK5Ac) are predictive of the clinical outcome of lung 
cancers. Seligson et al (58) discovered that lower cellular levels of H3K4diMe and H3K18Ac 
predict significantly poorer survival probabilities for lung cancer patients (60). It has been 
summarized that the status of acetylation and methylation of specific lysine residues 
contained within the tails of nucleosome core histones is crucial in regulating chromatin 
structure and gene expression (61, 62). 
In addition to this epigenetic function, certain HDACs also exhibit important cytoplasmatic 
function by controlling the acetylation status and function of numerous cytoplasmic 
proteins and transcription factors that may be important in carcinogenesis (63). Moreover, 
Sasaki et al (64) reported that expressions of HDAC1 correlated with the progression of lung 
carcinomas. Bartling et al (65) found HDAC3 upregulation in squamous lung cancers 
compared with non-tumor tissues in lung. Osada et al discovered that in a group of 72 lung 
cancer patients, the reduction of class II HDAC gene expression was clearly associated with 
poor prognosis (66). These results suggested that HDAC might be involved in lung cancer 
occurrence, progression, and prognosis and that inhibition of HDAC activity might be a 
possible target for lung cancer treatment.  
Increasing laboratory evidence has illustrated the therapeutic mechanisms of HDACi: e.g., 
HDAC inhibitor FK228 suppressed the PI3K/Akt (67) and Src/Raf/MEK/ERK1/2 (68) 
signaling pathways, resulting in the downregulation of the anti-apoptotic proteins Bcl-2 and 
Bcl-xL, upregulation of the pro-apoptotic protein Bax, and the induction of time-dependent 
apoptosis in both adenocarcinoma (69) and small cell carcinoma cells (69, 70). Coincident 
with inhibition of ERK1/2 and PI3K/AKT survival pathways, the HDAC inhibitor FK228 
enhanced JNK and p38MAPK signaling (68), whereas an SIRT1 inhibitor, Sirtinol, impaired 
activation of Ras/MAPK pathways in response to EGF and insulin-like growth factor-I (71). 
Furthermore, another HDAC inhibitor, trichostatin A, suppressed the levels of COX-2 
mRNA and protein expression, which were correlated with an inhibition in prostaglandin 
E2 synthesis in lung adenocarcinoma cells (69). Clearly, HDACi have a specific antitumor 
effect and thorough studies analyzing the full potential and mechanism of these drugs with 
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regards to optimal dose, schedule, patient selection and combination strategies would allow 
the development of molecules with more effective therapeutic effect. 
Recently, targeting HDAC activity using inhibitors of HDAC (HDACi) has become a novel 
and promising anticancer strategy, in particular in the treatment of advanced NSCLC where 
phase I and II trials have been completed (72). In addition, several HDACi have been shown 
to increase the cytotoxic effects of radiation in NSCLC by decreasing DNA repair efficiency 
and promoting cell death (73). HDACi also showed favorable results when used in 
combination with standard NSCLC chemotherapeutic agents and are likely to be a novel 
approach for the treatment of NSCLC because of an anti-growth activity against NSCLC 
cells (74, 75). Ongoing clinical trials are exploring the use of many new HDACi alone or as 
part of a combination with existing therapeutic modalities such as chemotherapy or 
radiotherapy (76).  
2.3 Micro-RNAs and lung cancer 
Micro-RNAs (miRNAs) are small non-coding RNAs with ~22 nucleotides in length (77, 78). 
miRNAs control a wide range of biological processes including apoptosis, development, 
proliferation and differentiation (78). High-throughput analyses have highlighted aberrant 
miRNA expression profiles in an increasing range of human cancer types (79-81) and all 
these studies suggested that cancer cells express altered miRNAs patterns consisting of both 
overexpression and downregulation. Therefore, miRNAs may function either as tumor 
suppressors or oncogenes and the genomic abnormalities found to influence their activity 
are the same as those described for protein-coding genes.  
To date, both laboratory and clinical studies demonstrate a deregulation of miRNA 
expression in lung cancer and highlight them as useful diagnostic, pronostic and therapeutic 
tools. A growing number of miRNAs has been found aberrantly expressed in lung cancer 
and our understanding of miRNA expression patterns and functions in normal and lung 
cancer cells is just starting to emerge. Such miRNAs as miR-21, miR-126, miR-31, miR-519c, 
Let-7a, miR-133B, miR-15a, miR-16, and miR-183 have been found to regulate lung cancer 
cell proliferation, migration and invasion by targeting specific molecules, including Crk, 
EGFL7, VEGF, LATS2, PPP2R2A, HIF-1α, NIRF, MCL-1, Bcl-2, cyclins D1, D2 and E1, and 
Ezrin (82-89). 
Growing evidence indicates that miRNA expression profiles confer important clues for 
clinical diagnosis and prognosis of human lung cancer. MicroRNA microarray analyses 
have identified profiles which could discriminate lung cancers from noncancerous lung 
tissues, as well as molecular signatures that differ according to tumor histology (80, 90). 
Interestingly, recent identification of Has-miR-205 has suggested it to be a highly specific 
marker for squamous carcinoma (91), therefore a clinical diagnostic assay based on miR-205 
expression levels could aid the differential diagnosis of NSCLCs. Since miRNAs are more 
stable than mRNA and more tissue specific than DNA, their measurement could provide a 
novel and promising non-invasive approach to discriminate between normal and cancer 
patient samples. Studies found that aberrant miRNA expression could be used as a marker 
for the diagnosis of NSCLC in sputum specimen (92) and miRNA expression in peripheral 
blood or in serum correlated well with its expression in the tumor sample (93). 
In terms of prognostic value, several miRNAs are reported to be associated with the clinical 
outcome of lung cancer. For instance, clinical study indicated that overexpression of mature 
miR-21 in the tissue and sputum samples could be an independent negative prognostic 
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factor for overall survival in NSCLC patients (94). Detection of miR-21 expression in sputum 
as a non-invasive approach for the diagnosis of lung cancer confers better sensitivity than 
sputum cytology (92). Clinical studies also showed reduced let-7 (81) and miR-34 (95) 
expression or enhanced miR-146b (96) and miR155 (80) expression with short survival or a 
high probability of relapse in patients with NSCLC. In patients with NSCLC, a five-miRNA 
signature including miR-221, let-7a, miR-137, miR-372, and miR-182 was identified and 
validated as an independent predictor of cancer relapse and survival (97). Remarkably, this 
signature is valuable even after patient stratification by stage or histology. In addition, 
expression levels of miR-486, miR-30d, miR-1, and miR-499 in serum could be used to 
predict survival for patients with NSCLC (98). Overexpression of miR-155 correlates with a 
poor prognosis when all clinical variables are considered together (80). Since miRNAs are 
upstream regulators of gene expression, they may be more powerful prognostic markers 
than their downstream target genes. For example, miR-146b alone was found to have a 
predictive accuracy for prognosis in ~78% of patients with lung squamous cell carcinoma 
(96), better than the overall predictive accuracy of 68% for a 50-gene signature (99). 
The potential for using miRNAs in lung cancer therapy is now being explored. Let-7 
overexpression confers radio-sensitivity to lung cancer cells (100). miR-128b LOH, a direct 
regulator of EGFR, correlates with clinical response and survival following gefitinib 
treatment (101). miR-221, miR-222 and miR-17-92 sensitize lung cancer cells to cytotoxic 
agents (102-104). Such results offer the experimental bases for the use of miRNAs as 
therapeutic targets. Further experiments are needed to uncover the emerging power of small 
non-coding RNAs to improve lung cancer therapeutics, and would have significant 
consequences for cancer patients in clinic. 
Accumulative scientific evidence suggests that cancer, particularly lung cancer, is not only a 
genetic disease (2, 3), but also an epigenetic disease. Laboratory and clinical studies clearly 
demonstrate that many aberrant epigenetic events occurring before the genetic changes are 
responsible for the cancer initiation and progression. It has been confirmed that disruption 
of the normal epigenetic processes promotes lung carcinogenesis and lung tumor growth 
through complicated mechanisms involving TSGs silencing and oncogene activation. 
Majority of these disruptions are found to be the consequence of exposure to environmental 
carcinogens, particularly from cigarette smoking causing heritable epigenetic changes. The 
management of aberrant epigenetic states as a way to target early lung cancer development 
or lung tumor progression is therefore a logical therapeutic approach. 
In the future, to develop new anti-tumor agents, such as DNMTi or HDACi, and the specific 
treatment strategies including tumor-targeted drug delivery system and specific 
administration routes, and to avoid the non-specific toxicity of anti-cancer drugs, will be of 
particular interest. Indeed, the side effects of these epigenetic compounds may have 
unscheduled consequences in terms of gene expression, in that they may display growth-
promoting effects on tumor cells. As more critical miRNAs are found and the expression of 
many of them reduced in lung cancer cells, targeting miRNA is becoming a promising 
strategy in terms of cancer treatment. Administration of synthetic oligonucleotides that 
mimic endogenous miRNAs might be used to treat specific tumor types if an effective 
delivery system can be developed. Moreover, targeting oncogenic miRNAs through 
administration of anti-sense oligonucleotides, called anti-miRNA oligonucleotides (AMO) is 
coming into focus, given that the use of antagomirs, which are AMOs conjugated with 
cholesterol, has emerged as an efficient approach to inhibit miRNA activity (105). Further 
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studies to uncover the potential usefulness of chromatin modifying drugs in restoring the 
loss of expression of tumor suppressor miRNAs are underway. There is no doubt that a 
more comprehensive dissection of the cellular and molecular pathways controlled by 
epigenetic processes will provide new insights into cancer related mechanisms and will 
highlight promising fields for the development of novel therapies to fight lung cancer. 
3. A preclinical study to use demethylating agent to treat orthotopic human 
lung cancer xenografts 
Lung cancer has remained as the number one cause of cancer-related deaths worldwide for 
decades (106). Traditional methods are mainly non-specific cytotoxic radiation therapy and 
chemotherapy; their non-specificity and therefore, life-threatening toxicity determined their 
limitation in the application. There is an urgent need to develop more sensitive diagnosis 
and more effective therapeutic methods to save lung cancer patients. About 90% of lung 
cancer cases are the end result of cumulative aberrant epigenetic changes and genetic 
damage to the respiratory epithelium chronically exposed to environmental, particularly 
tobacco carcinogens (107-109). One of the well accepted mechanisms of carcinogenesis in 
lung cancer is the aberrant methylation of CpG islands in the promoter regions of tumor 
suppressor genes (TSGs) leading to underexpression or absence of the proteins of those 
genes thus propagating tumorigenesis (110).  
It has also been proved that the promoter hypermethylation down regulated TSGs can be 
reversed by DNA-methyltransferase inhibitors (DMTI) like azacytidine (Aza), Aza-2’-
deoxycytidine, and Zebularine (11, 111, 112). These agents have been in clinical treatment 
for NSCLC patients by systemic administration with high doses and limited efficacy.  
Inhalation of carcinogens, mainly as a result of tobacco exposure, causes a field 
cancerization effect thereby placing the entire bronchial epithelium at risk of developing 
bronchogenic carcinoma. Any strategies that aim at decreasing the incidence of lung cancer 
or decreasing the incidence of a second primary in a patient with a history of lung cancer 
would have to have an effect on the entire bronchial epithelium. In the case of a 
pharmacologic agent, this would be possible and feasible by inhalation of aerosolized 
solution of the drug. DMTI agents like Aza have the potential to reexpress tumor suppressor 
genes, which might lead to reversal of premalignant changes, slow the carcinogenesis 
process, and eventually decrease the incidence of bronchogenic carcinoma (113). Systemic 
administration of these drugs has been explored in advanced NSCLC patients but not 
pursued because of significant systemic toxicity (114).  
In this part we present a study with two objectives: 1. To prove that whether reversing the 
hypermethylation in promoter region of the TSGs can make a positive contribution to the 
therapeutic outcome of lung cancer. 2. To prove whether the airway administration more 
effective than systemic administration to treat airway localized advanced bronchial 
premalignancy or endobronchial lung cancer. In this study, we used intratarcheal injection 
of Aza to treat the orthotopic lung cancer models in mice, the low dose (non-cytotoxic dose) 
we used mainly brought demethylating effect of Aza and avoided its cytotoxic effect. 
3.1 Experimental design and methods 
In order to prove whether demethylation on the hypermethylated promoters of TSGs will 
contribute therapeutic efficacy in the preclinical level, we tested the demethylation function 
of a typical demethylation agent azacytidine (Aza) in vitro and in vivo. Particularly, we 
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used intratracheal injection of Aza to treat orthotopic lung cancer xenografts in the efficacy 
study. The detailed experimental studies are presented below. 
We selected three different human non-small cell lung cancer cell lines for the in vitro and in 
vivo studies: a squamous cell carcinoma cell line H226, a bronchioalveolar carcinoma cell 
line H358, and a metastatic large cell carcinoma H460 from pleural effusion. All cell lines 
were purchased from American Type Culture Collection (ATCC, Manassas, VA) and 
cultured per ATCC’s protocols.  
3.1.1 In vitro studies  
In order to distinguish the cytotoxic effect and demethylation effect of Aza, we used MTT 
assay to determine the growth inhibition range of Aza and methylation-specific PCR with 
the samples treated by a set concentrations of Aza to detect the minimal concentration for 
the effective demethylation at the promoter region of TSGs. MTT assay used was literature 
method (115), briefly, ~5,000 cells in 0.135 µL RPMI 1640/well were seeded in 96-well plates. 
After 24 h of culture, Aza at various concentrations was added to the cells. Three days later, 
the cells were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and lysed. The absorbance of each well was measured in a microplate reader at 570 
nm. The percent growth inhibition of the cells was calculated as the absorbance of treated 
cells normalized to no treatment cells. 
We selected RASSF1a as the first candidate TSG to prove the concept. Because it was found 
silenced by promoter hypermethylation in 32.6% of NSCLC patients (116). The human 
NSCLC cells H226 were treated with Aza at 0.1, 1, and 10 ng/ml. On day 4 after the 
treatment, the cells were harvested. About 8 x 104 cells were used to detect the methylation 
status of the RASSF1a promoter using EZ DNA Methylation-Direct KitTM (Zymo Research 
Corp., Orange, CA, USA), according to the manufacturer’s instructions. The bisulfate-
converted DNA was then used as a template for methylation-specific PCR reactions using 
primers specific for either the modified methylated or modified unmethylated promoter 
sequences of the RASSF1a genes. The primers used have been described previously by 
others (117). The sequences are: methylated: 5’-GGG TTT TGC GAG AGC GCG-3’ (forward) 
and 5’-GCT AAC AAA CGC GAA CCG-3’(reverse); unmethylated: 5’-GGT TTT GTG AGA 
GTG TGT TTA G-3’(forward), and 5’-CAC TAA CAA ACA CAA ACC AAA C-3’(reverse). 
Briefly, PCR reactions contained 1-4 microliters of bisulfate-converted DNA, purified as 
above, 300 ng each of forward and reverse primers, 45 microliters of Platinum® PCR 
SuperMix (Invitrogen), and distilled water to a final reaction volume of 50 microliters. PCR 
amplification conditions were as described in the literature (117), unless otherwise noted. 
The PCR products were separated on 2% agarose gels containing ethidium bromide and 
were visualized under UV illumination.  
3.1.2 Animal studies  
The studies were begun from testing acute toxicity and finding the therapeutic dose. CD-1 
mice (Harlan) were used to evaluate and compare the acute toxicities of Aza by the 
intratracheal or intravenous routes. Two groups of mice (5-8 mice/group) were treated with 
90 mg/kg of Aza via intravenous injection (IV) or intratracheal injection (IT), respectively. 
The dose of 90 mg/kg is the maximum tolerated dose (MTD) of IV Aza in mice. The IV and 
IT injection methods were described previously (12, 118). Briefly, for the IT the mice were 
anesthesized with intraperitoneal injection of 30-50 mg/kg of Nembutal or isoflurane 
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inhalation, fixed on the small animal fixing board. The mouth of mouse was open with a 
forceps; the drug solution or cell suspension was carefully injected into the trachea through 
mouth via a 22-gage feeding needle attached to a 1 ml syringe. The injection volume did not 
exceed 100 µl/mouse. If necessary, a “tube” type of light inserting into the mouth can be 
used to help locate the trachea.  
For myelotoxicity assessment, blood (100 µl/mouse, 5 mice/group) was drawn from the tail 
vein before treatment (at day 0) and on days 4, 7, 14, and 28 after treatment. Red blood cells 
(RBC) were removed from the blood samples using RBC lysis buffer (eBioscience San Diego, 
CA) as per the manufacturer’s protocol. White blood cells (WBC) were collected and 
counted with a hematocytometer under a microscope. Blood samples from mice without 
treatment were used as controls. In the organ toxicity studies, groups of mice given IT of 
Lactated Ringer’s Solution or without treatment were used as vehicle and normal controls, 
respectively. Creatinine levels, and liver function tests were determined at Antech Diagnosis 
(Lake Success, NY). Organ pathological examination was performed at different time points. 
Briefly, 5 mice in each group were euthanized on day 4, 7, 14, and 28 days after 
administration of the drug. Blood was drawn from the caudal vena cava, and lungs, livers 
and kidneys were resected and fixed with 10% buffered Formalin. The fixed tissues were 
processed with standard procedure for H&E staining. The toxicity levels were determined 
by giving toxicity grade to each tissue sample. The grading based on the general pathology 
guidelines was 0 to 4, they reflect a percentage of damaged tissue of 0, <10 (mild), 10-30 
(moderate), 30-60 (severe), >60 (life threaten), respectively.  
To mimic human NSCLC, we developed a mouse model by intratracheal inoculation of 
human lung cancer cells in nude mice (12). Briefly, the nude mice (in this particular 
example, male and female NCRNU-M-F nude mice, 6-7 weeks old, purchased from Taconic 
Farms, Germantown, NY) were given tumor inoculation with 2~5 x 106 cells/mouse by IT 
described above. In this model, we found that the cancer cells initially attached on the 
airway epithelium of the mice and survived (from day 0 to 10), and then they formed micro 
nodules in the airway (from day 7 to 21), and finally the tumors invaded lung tissue (from 
day 14 to 35). The tumors mainly remain in the lung during the rest of lifetime of the mice, 
and the animal on average die on day 45 to 70 from the lung tumor burden (13). This model 
mimics the human NSCLCs that develop on the airway epithelium before they invade the 
lung parenchyma, and it is one of human lung cancer relevant models to evaluate lung 
cancer therapeutics by different administration routes, particularly by airway 
administration. 
In the antitumor efficacy test, we used a relative low dose of Aza with intratracheal injection 
to avoid the cytotoxic effect and emphasize the demethylation effect of Aza. Ten days after 
the intratracheal tumor inoculation, the nude mice were randomly divided into 3 groups of 
5 mice each in each test, and were treated with daily intravenous injection (IV) of Aza at 6.25 
mg/kg/day x 6 doses or intratracheal injection (IT) of Aza at 2.5 mg/kg/every other day x 3 
doses. The IT used the same method of the tumor inoculation described above. These 
optimal doses for the therapeutic study were determined in prior dose ranging studies. A 
group of mice without treatment was used as control. Survival was used as the major 
endpoint to evaluate efficacy.  
The same Aza formulation was used for the IT and IV treatment. It was made by dissolving 
azacytidine powder (Sigma, St Louis, MO) in Lactated Ringer’s Injection (Hospira, Inc., Lake 
Forest, IL) and passing the solution through 0.22 µm filter immediately prior to use. 
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3.1.3 Statistical analysis  
Differences among different groups were analyzed by two-side Log Rank Assay. A 
difference was considered statistically significant when p < 0.05.  
3.2 Results 
3.2.1 Growth inhibition and demethylation function of Aza in human NSCLC cell lines 
Aza has the both functions. In order to know whether Aza’s demethylation effect can 
function at a non-toxic concentration, we measured its cell growth inhibition and 
demethylation function in the selected human NSCLC cell lines. We found that Aza 
inhibited the growth of the NSCLC cells in a dose dependent manner as shown in Figure 1. 
The 50% inhibitory concentrations (IC50) of Aza were 0.6, 3.4, and 4.9 µg/ml in H226, H358, 
and H460 cells, respectively. In this study, Aza at a concentration below 0.6 µg/ml did not 
cause significant growth inhibition in all tested cell lines.  
 
 
Fig. 1. Growth inhibition of Aza on human NSCLC cell lines. H226, H358, and H460 cells 
were treated with (5-fold) increasing concentrations of Aza. The percentage of growth 
inhibition was measured with MTT Assay. The data for each cell line are mean ± standard 
deviation obtained from 3 independent experiments.  
The demethylation function of Aza were detect by a methylation-specific PCR method in the 
H226 NSCLC cell line at a very low concentration range (0.1 ~ 10 ng/ml). As shown in 
Figure 2, the unmethylated band (#5) of the promoter of RASSF1a gene was found in the 
H226 cells at the lowest concentration of 0.1 ng/ml, which is 6000-fold lower than the IC50 
of Aza in the same cell line. This indicates that when directly exposing lung cancer cells to 
Aza, Aza can function as effective demethylation agent at an extremely low concentration 
without causing any direct cytotoxicity.  
3.2.2 Intratracheal administration of Aza results in significantly reduced toxicity 
Myelosuppression is the dose-limiting toxicity of intravenously administered Aza when 
used clinically. In this study, we compared the myelotoxicity of IT and IV Aza at the same 
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dose, 90 mg/kg that is MTD when using IV administration. IT Aza produced significantly 
less myelotoxicity than IV Aza at the MTD of IV Aza. As shown in Figure 3, IV Aza 
significantly reduced the total WBC by > 68% on day 4 and 7 (p < 0.004) and >38% on day 14 
(p < 0.006), the WBC count recovered to about 90% of the normal level on day 28. While the 
only detectable WBC reduction in IT Aza treated mice was about 13% on day 7 (p < 0.01). 
The recovery was faster (on day 14) and complete (>97% of the normal level, p > 0.5) 
compared with IV Aza (Figure 3).  
 
 
Fig. 2. The demethylation function of Aza in the NSCLC cells. H226 human NSCLC cells  
(8 x 104 cells) were treated with Aza at 0.1, 1, and 10 ng/ml. The methylation status of the 
RASSF1a promoter was detected by methylation-specific PCR method using the EZ DNA 
Methylation-Direct Kit. The pair of bands from 1 to 3 are samples of water, methylated DNA 
control, and unmethylated DNA control; from 4 to 7 are samples of H226 cells treated with 
Aza at 0, 0.1, 1, and 10 ng/ml, respectively. The letters “U” and “M” represent 
unmethylated and methylated detection, respectively.  
 
Fig. 3. IT administration of Aza is 5-fold less myelosuppression compared to IV Aza. Aza 
was administered IT (round dots) or IV (triangle dots) at a dose of 90 mg/kg. Control mice 
were not given any treatment (square dots). Blood was drawn on day 0, 4, 7, 14, and 28 after 
treatment. WBC was counted after removal of red blood cells. The data of each group (5-8 
mice each) are mean ± standard deviation.  
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To know whether the IT Aza will cause the locoregional toxicity or systemic toxicity in other 
organs, an organ toxicity study in a scope of acute toxicity of IT Aza were performed and 
the IV Aza was used as comparison. At the MTD, the results of serum liver function  
tests and serum creatinine measurements were normal for all mice and there were no 
differences among the groups of IT Aza, IV Aza, and no treatment (data not shown). On 
histopathological evaluation, no liver or kidney toxicities were identified in any treatment 
group (data not shown). By lung histological evaluation, moderate pulmonary toxicity was 
observed in all 5 animals in the IT Aza group on day 7 but not at the other time points. Of 
note is that the IT dose used in these experiments is 12-fold higher dose than the optimized 
total dose used in the therapeutic experiments. The lung toxicity was described as moderate 
pneumonitis, characterized by type II pneumocyte hypertrophy, neutrophilic infiltration, 
and lymphohistiocytic inflammation (Figure 4, photograph 2). As stated, no pulmonary  
 
 
Fig. 4. IT Aza at the therapeutic dose does not produce pulmonary toxicity. ICR mice were 
intratracheally injected with 90 mg/kg of Aza, 2.5 mg/kg qod x 3 of Aza, or the equal 
volume of vehicle (Lactated Ringer’s Injection). The lungs of mice were resected on day 4, 7, 
and 14 after injection. Standard H & E staining of lung tissues was used to assess pulmonary 
toxicity. Photographs 1 to 6 are the lungs from mice receiving 90 mg/kg of IT Aza (1~3) or 
the same volume of IT vehicle (4~6). Photograph 7 is the lung from mice receiving the 
therapeutic dose of IT Aza (2.5 mg/kg, qod x 3) on day 7 post the final injection. Photograph 
8 is the lung from untreated mice.  
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toxicity was observed in animals treated with IT Aza on days 4 or 14. At the optimal 
therapeutic dose (2.5 mg/kg, qod x 3), IT Aza did not cause lung toxicity (Figure 4, 
photograph 7) and any other toxicity (data not shown). The pulmonary toxicity grades are 
listed in Table 1. These results indicate that the pulmonary toxicity caused by IT Aza at 
supratherapeutic doses (the MTD of IV Aza) is moderate (photograph 2) and reversible 
within 2 weeks (photograph 3). IT Aza at the therapeutic dose, IT vehicle, and IV Aza (data 
not shown) did not cause detectable pulmonary toxicity.  
 
Day 4 7 14 28 
IT Aza (90 mg/kg) 0* 2* 0* 0 
IT Aza (2.5 mg/kg x 3) 0 0* 0 0 
IT Vehicle 0* 0* 0* 0 
IV Aza (90 mg/kg) 0 0 0 0 
No Treatment 0 0* 0 0 
 * histopathological photographs are shown in Figure 3. 
Table 1. Toxicity grade of lungs of the mice treated with IT Aza 
3.2.3 Intratracheal administration of Aza significantly prolonged the survival of mice 
bearing orthotopic human NSCLC xenografts 
To evaluate the efficacy of IT Aza in clinically relevant NSCLC models, we inoculated the 
human NSCLC cell lines H266, H358, and H460 into the lungs of nude mice via the trachea. 
These models mimic closely orthotopic human NSCLC. In mice, small mucosal tumor 
nodules are evident at 1-3 weeks after the inoculation of tumor cells. In the absence of any 
intervention, the mice succumb to the tumor in 6-10 weeks. The survival curve in these 
models closely correlates with the tumor burden (13), and can be utilized as an endpoint for 
the evaluation of treatment efficacy.  
Treatments were initiated on day 10 post tumor inoculation. The survival observed in 
mice treated with IT Aza was compared to that in mice treated with IV Aza and untreated 
tumor-bearing mice. Animals in each treatment group were given multiple injections; 
these doses and schedules were optimized in a preliminary study (data not shown). The 
total dose was 7.5 mg/kg for IT Aza (2.5 mg/kg, qod x 3) and 37.5 mg/kg for IV Aza (6.25 
mg/kg, qd x 6). Both dose levels are significantly lower than the corresponding MTD’s. 
Results are shown in Figure 5. IV Aza had limited efficacy against three lung cancer 
models at the optimal therapeutic dose: the median survival increased by 10% in H226 
model (72 vs. 67), , and 22% in the H358 model (73 vs. 60 days, p > 0.05) and 60% in the 
H460 model (80 vs. 50 days, p < 0.01), whereas IT Aza demonstrated significantly 
increased efficacy: the median survival increased by 107% (139 vs. 67), 63%, (98 vs. 60 
days, p < 0.006), and 142% (121 vs. 50 days, p < 0.002) in the H226, H358, and H460 model, 
respectively. The increased lifespan (%ILS) (119) of IT Aza treated mice bearing H226, 
H358, or H460 lung tumors was 3.2- to 8.6-fold higher than that of IV Aza treated mice 
(96.2% vs. 11.2%; 75.8% vs. 21.5%; 131.3% vs. 40.7%). The efficacy of each treatment is 
summarized in Table 2. 
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Fig. 5. Intratracheal administration of low dose Aza significantly prolongs survival of mice 
bearing orthotopic human NSCLC xenografts. Mice intratracheally inoculated with H226 
(left), H358 (middle), or H460 (right) human NSCLC cell lines were treated with IT Aza 
(thick line) or IV Aza (dash line) on day 10 at a dose of 2.5 mg/kg qod x 3 for IT and 6.25 
mg/kg daily x 6 for IV. The control was a group of untreated mice (thin line).  
 




67 (50~84) 72 (55~101) 139 (89~178) 1.93 
0.016 





60 (46~75) 73 (54~93) 98 (75~146) 1.34 
0.018 




50 (42~75) 80 (58~100) 121 (75~183) 1.51 
0.005 
%ILS 0 40.7 131.3 3.23 
Table 2. Efficacy summary 
3.3 Discussion 
Azacytidine (Aza) is approved by the Food and Drug Administration for the treatment of 
myelodysplastic syndromes (11), a preleukemic condition, and has potential for the 
treatment of other cancers and premalignant conditions as a result of a cytotoxic effect, a 
DNA demethylating effect, or both. As a cytotoxic agent in proliferating cells, Aza can 
disrupt RNA metabolism, DNA synthesis, and protein synthesis. Particularly, Aza is 
incorporated into DNA and inhibits DNA methyltransferases and causes hypomethylation 
of replicating DNA (120, 121) which can result in re-expression of tumor suppressor genes 
silenced by hypermethylation. From 1973 to 1977, there were at least 9 clinical studies in 
solid tumor patients with intravenous Aza, which included 78 lung cancer patients (122). 
The therapeutic efficacy observed was limited, possibly due to two major reasons: First, the 
studies were performed in advanced lung cancer patients where reversal of 
hypermethylation per se may not be sufficient to have a therapeutic impact; second, all the 
studies were done using systemic administration or a sub-optimal dose schedule, which 
limits the use of these agents as a result of systemic toxicity. The studies presented here 
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were designed to provide the foundation for the potential use of a regional demethylation 
strategy for malignant or premalignant conditions of the bronchial epithelium in which 
DNA hypermethylation plays an important role. We used Aza as a model compound and 
tested its toxicity and antitumor efficacy by direct delivery in the respiratory airways via the 
trachea in models of endobronchial human NSCLC. Our studies demonstrate that IT Aza 
produced a 5-fold reduced myelosuppression (as assessed by WBC nadir) than IV Aza at a 
dose equivalent to the IV MTD and 3-fold higher antitumor efficacy (as assessed by %ILS) at 
a dose 5-fold lower than that of IV Aza, the end-result being a 75-fold increased therapeutic 
index. These results justify continuing exploring regional demethylating therapy for the 
treatment of malignant or premalignant conditions of the lungs that are easily accessible 
through the airways, including advanced premalignancy, bronchioalveolar carcinoma, and 
small parenchymal metastatic disease. 
Lung cancers develop in the epithelium in direct contact with the airways because 
carcinogens reach the lungs through inhalation. Bronchial premalignancy, carcinoma in situ, 
small primary or metastatic tumors, and some cases of BAC are theoretically more accessible 
via the endobronchial space than through the bloodstream. Aerosol approaches to the 
treatment or prevention of these conditions are therefore a more logical therapeutic strategy 
than systemic treatment. However, in the present studies we used intratracheal 
administration rather than aerosol administration because the purpose was proof of concept 
and administration of drugs by aerosolization to mice is inefficient. The major difference 
between these two types of drug administration (IT vs. aerosol) would be a higher 
distribution of the drug to the alveolar space with aerosol administration. We are currently 
conducting studies to validate the results presented here using the clinically available 
formulation of Aza administered by aerosolization to mice.  
Our toxicity studies demonstrate, as expected, that Aza given IT results in a 5-fold reduced 
myelosuppression, which is the dose-limiting toxicity of IV Aza. Most importantly, IT Aza 
at 90 mg/kg only caused moderate pulmonary inflammation on day 7 after IT 
administration. It was encouraging to see that there was no evidence of lung inflammation 
on day 14 post IT Aza, even when the dose used for IT was as high as the maximum 
tolerated dose using the IV route. In the efficacy experiments, the optimal total IT dose used 
was 12 fold lower, a dose did not cause any pulmonary toxicity. To confirm this, we are 
currently performing more refined lung toxicity studies in the context of our current 
therapeutic experiments using aerosolized administration.  
In the efficacy experiments, the efficacy (%ILS) of IT Aza at a 5-fold lower dose was 3.2- to 
8.6-fold superior to that of IV Aza in mice with endobronchial H226, H358, or H460 tumors. 
These results indicate that the regional administration route into the airways is more 
efficient than the intravenous route for the treatment of endobronchial tumors. The main 
therapeutic potential of airway-administered Aza is secondary prevention of NSCLC due to 
the field cancerization effect of inhaled carcinogens via tobacco smoke. The proposed 
mechanism would be hypomethylation of CpG islands of the promoter regions of tumor 
suppressor genes thereby inhibiting development of dysplasia and progression of dysplasia 
to cancer. In these studies, we used a mouse model of endobronchial tumors but not 
dysplasia. We are currently developing an animal model of lung premalignancy in mice by 
exposing them to tobacco carcinogens directly into the upper airways. We plan to test the 
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In these studies, the efficacy endpoint was survival secondary to antitumor effect in models 
of malignancy. In the anticipated clinical scenario, the intermediate efficacy endpoint would 
be changes in hypermethylation patterns or effective gene reexpression. In this study, the 
optimal therapeutic dose was 12-fold lower than the maximum tolerated dose (MTD). This 
finding suggests that this strategy may have a large therapeutic window and that the risk of 
acute or chronic side effects might be very low if these agents were used at optimal doses 
rather than MTD. Therefore, determining optimal doses based on pharmacodynamic 
assessments in patients enrolled in clinical studies with this new therapeutic strategy are 
essential to minimize the potential side effects. Particularly, the potential carcinogenicity of 
this approach could become an important limitation if benefit was demonstrated but 
required chronic administration of unnecessarily high doses of these agents. Therefore, in 
the context of our initial Phase I clinical study of inhaled Aza we intend to monitor 
methylation patterns as well as gene reexpression in the target tissue pre and post-therapy 
to establish an optimal dose based on target effects rather than a maximum tolerated dose.  
In vitro, we have proved that Aza can effectively demethylate the hypermethylation in the 
promoter of tumor suppressor gene at a non-toxic concentration. In vivo, we found that IT 
Aza are effective against experimental lung cancer by prolonging the life of the mice bearing 
orthotopic lung tumors without causing any detectable systemic or locoregional toxicity. 
Here the functions of both the epigenetic effect and the locoregional administration played 
an important role. We believe that the lung-specific epigenetic treatment with Aza has great 
potential to reduce the tumor burden by reversing the hypermethylation in the promoters of 
the tumor suppressor genes and therefore reactivating the silenced genes. This is an 
important project to be further studied.  
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